Satisfaction of Patients With the Chosen Method of Inhibition of Lactation

Sponsor
Żelazna Medical Centre, LLC (Other)
Overall Status
Recruiting
CT.gov ID
NCT04038749
Collaborator
(none)
90
1
3
42.5
2.1

Study Details

Study Description

Brief Summary

The aim of the study is to improve the standard of care in case of the inhibition of lactation.

The participant qualified for the study will answer the questions contained in the survey. The patient will have her breast palpated and then will be instructed on the possible options for the inhibition of lactation. The participant, who decides to inhibit lactation with medications, will be consulted by a doctor.

Each patient will receive information of the possible ways to relieve the symptoms of overfilled breast and be able to contact with lactation consultant. The participant will also receive a card to assess the severity of symptoms in the following days. The investigators will call the patient between the third and fifth day by phone.

Once again, after 2 weeks from the beginning of the inhibition of lactation in order to ask questions contained in the survey (the course of the process, problems that occurred and the level of satisfaction with the chosen method).

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Satisfaction of Patients With the Chosen Method of Inhibition of Lactation: With the Use of Drugs Lowering the Level of Prolactin or Without the Use of Pharmacological Agents in Postnatal Period, Taking Into Account Individual Conditions
Actual Study Start Date :
Jun 16, 2019
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Pharmaceutical method- Bromocriptine

Drug: Bromocriptine
Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
Other Names:
  • Bromergon
  • Other: Natural methods
    milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.

    Experimental: Pharmaceutical method- Cabergoline

    Drug: Cabergoline
    Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
    Other Names:
  • Dostinex
  • Other: Natural methods
    milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.

    Other: Without medications that inhibit lactation

    Other: Natural methods
    milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.

    Outcome Measures

    Primary Outcome Measures

    1. Visual Analogue Scale (VAS) [from the 1st day of the inhibition of lactation to 14th day of process]

      Pain assesment by Visual Analogue Scale (VAS scale), range 0-10, higher numbers represents worse outcome.

    2. Evaluation of breast status [from the 1st day of the inhibition of lactation to 14th day of process]

      Daily evaluation of breast status. Are they: heavy, full, swollen (engorged), warmed up, hard, irregular, leaking. Gradations of symptoms intensity by using (+) and (-) where: "-" - means not at all "+" - means a little "++" - means a lot "+++" - means very (highest level)

    3. Symptoms in association with the ingestion of medicines that inhibit lactation. [from the 1st day of the inhibition of lactation to 14th day of process]

      headache constipation stomach pain general weakness somnolence vomiting dizziness nausea other Symptoms that occurred are marked with a "+".

    4. Breast palpation [1st day of including in the study]

      • Size (each one separately; left and right breast) hypoplastic small average big The correct answer is marked with a "+". • Anomalies (each one separately; left and right breast) no change swollen redness warming achiness scars The correct answer is marked with a "+".

    5. Survey: 1st day of including in the study [1st day of including in the study]

      Questions about: parturition, previous lactations, cause of lactation suppression, factors which may impair lactation, contraindications to medications that suppress lactation, current lactation, the way to suppress lactation.

    Secondary Outcome Measures

    1. Survey: 3rd-5th day of lactation suppression [3rd-5th day of lactation suppression]

      Question about: • ailments, problems and extra methods of relief of symptoms

    2. Survey: 14th-16th day of lactation suppression [14th-16th day of lactation suppression]

      Questions about: specific ailments and problems during the inhibition of lactation process (such as. pain, feeling of heaviness, temperature, low-grade fever/higher fever, stasis, mastitis, breast abscess, side effects caused by medications) applied methods to ease ailments: (milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea). assessment whether the decision on how to inhibit lactation was right

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Mother during the period of six weeks after childbirth

    • Decision to inhibit lactation

    • Patient's age at the time of enrollment (at least 18 years old)

    Exclusion Criteria:
    • Less than 18 years of age

    • Lack of patient's consent

    • To the pharmacotherapy group- contraindications for the use of the medication

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Żelazna Medical Centre Warsaw Poland

    Sponsors and Collaborators

    • Żelazna Medical Centre, LLC

    Investigators

    • Study Chair: Dorota Sys, PhD, Centre of Postgraduate Medical Education

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alicja Misztal, Investigator, Żelazna Medical Centre, LLC
    ClinicalTrials.gov Identifier:
    NCT04038749
    Other Study ID Numbers:
    • 23/2019
    First Posted:
    Jul 31, 2019
    Last Update Posted:
    Jul 31, 2019
    Last Verified:
    Jul 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 31, 2019